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Abstract
Background: Despite a generally high specificity, electrocardiographic (ECG) criteria
for the detection of left ventricular hypertrophy (LVH) lack sensitivity, particularly in
obesity patients.
Objectives: The aim of the study was to evaluate the accuracy of the most commonly
used ECG criteria (Cornell voltage and Sokolow-Lyon index), the recently introduced
Peguero-Lo Presti criteria and the correction of these criteria by body mass index
(BMI) to detect LVH in obesity patients and to propose adjusted ECG criteria with
optimal accuracy.
Methods: The accuracy of the ECG criteria for the detection of LVH was retrospec-
tively tested in a cohort of obesity patients referred for a transthoracic echocardio-
gram based on clinical grounds (test cohort, n = 167). Adjusted ECG criteria with
optimal sensitivity for the detection of LVH were developed. Subsequently, the value
of these criteria was prospectively tested in an obese population without known car-
diovascular disease (validation cohort, n = 100).
Results: Established ECG criteria had a poor sensitivity in obesity patients in both the
test cohort and the validation cohort. The adjusted criteria showed improved sensi-
tivity, with optimal values for males using the Cornell voltage corrected for BMI,
(RaVL+SV3)*BMI ≥700 mm*kg/m2; sensitivity 47% test cohort, 40% validation
cohort; for females, the Sokolow-Lyon index corrected for BMI, (SV1 + RV5/RV6)*
BMI ≥885 mm*kg/m2; sensitivity 26% test cohort, 23% validation cohort.
Conclusions: Established ECG criteria for the detection of LVH lack sufficient sensi-
tivity in obesity patients. We propose new criteria for the detection of LVH in obesity
patients with improved sensitivity, approaching known sensitivity of the most com-
monly used ECG criteria in lean subjects.
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1 | INTRODUCTION
The prevalence of obesity has increased rapidly, and nowadays more
people are obese than underweight.1 Left ventricular hypertrophy (LVH)
occurs frequently in obesity patients, even in the absence of com-
orbidities such as hypertension2,3 and is associated with increased risk of
cardiovascular disease, morbidity, and mortality.4-6 Although echocardi-
ography is a more sensitive tool to identify LVH, the standard electrocar-
diogram (ECG) remains widely used, because of its established clinical
value, broad availability, and low costs.7 ECG criteria for the diagnosis of
LVH have been used since 1914.8 Nowadays, the two most commonly
used ECG criteria are the Cornell voltage9 and the Sokolow-Lyon
index.10 Despite a generally high specificity, most ECG criteria for LVH
lack sensitivity.11 The value of these criteria is particularly questionable
in obesity patients12,13 because obesity is responsible for geometrical
and electrophysiological changes of the heart and ECG voltages may be
attenuated by subcutaneous adipose tissue.14,15 Recently, Peguero and
Lo-Presti introduced more sensitive ECG criteria for the detection of
LVH.16 Until now, these criteria have not been specifically tested in
obese subjects. Finally, Angeli et al.17 introduced a correction to the Cor-
nell voltage by body mass index (BMI) to improve the performance of
traditional ECG criteria.
The aim of the current study was to retrospectively evaluate the
accuracy of various ECG criteria to detect LVH in obesity patients and
to propose adjusted ECG criteria with optimal sensitivity for this
group of patients. Subsequently, the identified optimal criteria were
prospectively tested in an obese population without suspicion of or
known cardiovascular disease.
2 | METHODS
The accuracy of the Cornell voltage, Sokolow-Lyon index, Peguero-
Lo-Presti criteria, and the correction of Cornell voltage by BMI for
detection of LVH was retrospectively tested in obesity patients who
were referred for a transthoracic echocardiogram based on clinical
grounds (suspicion on or history of cardiovascular disease) (test
cohort). From these data, ECG criteria with optimal sensitivity for the
detection of LVH were developed by adjusting the cut-off values and
correcting all voltage criteria for BMI. After this, the value of these
criteria was prospectively tested in an obese population without sus-
picion of or history of cardiovascular disease (validation cohort).
2.1 | Test cohort
All obesity patients (BMI ≥35 kg/m2) who came to the Franciscus Gas-
thuis and Vlietland (Rotterdam, the Netherlands) in 2017 and under-
went both an ECG and transthoracic echocardiography were included
in the analysis. Patients with conditions potentially affecting the ECG
voltage amplitude, such as a left or right bundle branch block, a paced
rhythm, and imaging evidence of myocardial infarction or pericardial
effusion, were excluded.
2.2 | Validation cohort
All obese participants of the CARDIOBESE study18 were included for
the validation cohort. In short, the CARDIOBESE study was designed
to detect early signs of cardiac dysfunction in obesity patients without
a suspicion of or known cardiovascular disease. Patients with a BMI of
≥35 kg/m2 scheduled for bariatric surgery were included. All research
data acquisition was approved by the local research ethics committee
and informed written consent was obtained from each participant.
2.3 | ECG recording and analysis
A standard 12-lead ECG was recorded at a paper speed of 25 mm/s and
an amplification of 10 mm/mV. Heart rate, QRS duration, R-wave and S-
wave heights, and QRS axis were measured. Left axis deviation was
determined as QRS axis between −30 and −90. Measurements were
taken to the nearest 1 mm. The most commonly used ECG criteria were
analyzed (Figure 1): the Cornell voltage, RaVL + SV3 (considered positive
≥28 mm in male subjects and ≥ 20 mm in female subjects)9; Sokolow-
Lyon index, SV1 + RV5/RV6 (RV5 or RV6, whichever is greater; consid-
ered positive ≥35 mm)10; the Peguero-Lo Presti criteria, SV4 + Sdeepest
(considered positive ≥28 mm in males and ≥ 23 mm in females)16; and
the correction of Cornell voltage by BMI, (RaVL + SV3)*BMI (considered
positive ≥604 mm*kg/m2).17 Finally, we multiplied the Sokolow-Lyon
index and Peguero-Lo Presti criteria by BMI.
2.4 | Echocardiography
Two-dimensional (2D) grayscale harmonic images were obtained in the
left lateral decubitus position using a commercially available ultrasound
system (EPIQ 7, Philips, Best, the Netherlands), equipped with a broad-
band (1-5MHz) X5-1 transducer. All acquisitions andmeasurements were
performed according to current guidelines.19,20 Estimation of left ventricu-
lar mass (LVM) as determined by echocardiography was used as the
golden standard. Interventricular septal thickness (IVSd), posterior wall
thickness (PWd), and left ventricular dimension (LVEDD) were all mea-
sured at end diastole. The LVMwas calculated according to the Deveraux
formula using these measurements: LVM (g) = 0.80 × {1.04[(IVSd +
LVEDD + PWd)3-(LVEDD)3]} + 0.6. LVMwas abnormal if LVM ≥225 g for
males and ≥163 g for females. The LVM was divided by the body surface
area (BSA) to calculate the LVM-index (LVMI). BSA was calculated by the
Mosteller formula.21 LVH was defined as LVMI ≥102 g/m2 for males and
≥88 g/m2 for females.19
2.5 | Statistical analysis
To compare baseline characteristics between the two cohorts, the Stu-
dent t test was used for continuous variables and the χ2 test for categori-
cal variables. Continuous values were expressed as mean ± SD and
categorical values as percentages. The sensitivity, specificity, positive
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predictive values (PPV) and negative predictive values (NPV), and their
95% confidence intervals were calculated for the ECG criteria in both
groups. Differences in sensitivity and specificity between cohorts were
tested with the χ2 test. A two-tailed P value <.05 was considered statisti-
cally significant. Optimal cut-off values for all ECG criteria were manually
calculated for both genders by a receiver operating characteristic (ROC)
curve, using a fixed specificity of 95%.10,14,22,23 Area under the curve
(AUC) was calculated. Statistical analyses were performed with SPSS ver-
sion 25.0 or higher (SPSS Inc., Chicago).
3 | RESULTS
3.1 | Patient characteristics
A total of 194 patients were included in the test cohort and 100 in
the validation cohort. Twenty-seven patients were excluded in the
test cohort; five patients because of a paced rhythm, 15 patients
because of a bundle branch block, and seven patients showed wall
motion abnormalities on echocardiography. No patients were
excluded due to poor echocardiographic windows.
Patients in the test cohort were older, had a higher heart rate and
more comorbidities such as diabetes mellitus and hypertension
(Table 1). Patients in the validation cohort had a higher BSA (2.3 ± 0.2
vs 2.5 ± 0.2 m2, P < .001) compared to the test cohort. LVM (197
± 67 vs 196 ± 63 g, P = .83), and LVMI (94 ± 81 vs 79 ± 22 g/m2,
P = .13) were not significantly different between groups. However,
the prevalence of LVH (defined as an increased LVMI) was higher in
the test cohort (31.7% vs 19.2%, P < .05). LVH criteria as measured by
ECG and echocardiography were stratified by gender as well (Table 2).
There were no significant differences between male and female
patients in both groups regarding abnormal ECG criteria. Also,
although LVMI was increased in males as compared to females, preva-
lence of abnormal LVMI was comparable.
3.2 | Accuracy of established criteria for detection
of LVH in obesity patients (test cohort)
The BMI adjusted Cornell voltage had the highest sensitivity (53%
male, 32% female) followed by the Peguero-Lo Presti criteria (16%
male, 9% female). The Sokolow-Lyon index had very poor sensitivity
(0% male, 3% female) in this obese population (Table 3). On the other
hand, the specificity of the criteria not multiplied by BMI was high
(ranged from 96% to 100%), but relatively low for the BMI adjusted
Cornell voltage (72% male, 85% female).
3.3 | Accuracy of adjusted criteria for detection of
LVH in obesity patients (test cohort)
New cut-off values for both males and females were defined for all
criteria, with a fixed 95% specificity. The new cut-off values for the
Cornell voltage, Sokolow-Lyon index, and Peguero-Lo Presti criteria
F IGURE 1 Electrocardiogram of a 67-year-old male obesity patient that meets the criteria for left ventricular hypertrophy based on the
adjusted Cornell voltage*BMI, (RaVL+SV3)*BMI ≥700 mm*kg/m2. The diagnosis of left ventricular hypertrophy was confirmed by an
echocardiogram. Note that none of the other criteria were positive. BMI, body mass index
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were, respectively, ≥20, 24, and 19 mm for females and ≥27, 27, and
23 mm for males. All criteria were multiplied by BMI. The optimal cut-
off values for the Cornell voltage*BMI, Sokolow-Lyon index*BMI, and
Peguero-Lo Presti criteria*BMI were, respectively, ≥795, 885, and
780 mm*kg/m2 for females and ≥700, 984, and 900 mm*kg/m2 for
males. Using these adjusted cut-off values, the Cornell voltage*BMI,
(RaVL+SV3)*BMI ≥700 mm*kg/m2, had the best sensitivity for males
(47%, CI: 25%-70%), specificity 96% (CI: 78%-100%), ROC AUC 0.65,
PPV 90% (CI: 54%-99%), and NPV 71% (CI: 52%-84%). The Sokolow-
Lyon index*BMI, (SV1 + RV5/RV6)*BMI≥885 mm*kg/m2, had the
best sensitivity for females (26%, CI: 14%-45%), specificity 93% (CI:
85%-97%), ROC AUC 0.69, PPV 60% (CI: 33%-83%), and NPV 77%
(CI: 68%-84%).
3.4 | Prospective validation of the adjusted criteria
for detection of LVH in obesity patients (validation
cohort)
When the new criteria were tested in the validation cohort, again the
adjusted Cornell voltage*BMI had the best sensitivity for males (40%,
CI: 7%-83%), specificity 92% (CI: 71%-99%), ROC AUC 0.78, PPV
50% (CI: 9%-91%), and NPV 88% (CI: 68%-97%). The Sokolow-Lyon
index*BMI again had the best sensitivity for females (23%, CI: 6%-
54%), specificity 83% (CI: 70%-91%), ROC AUC 0.57, PPV 25% (CI:
7-57%), and NPV 81% (CI: 68%-90%). None of the male patients in
the validation cohort had a positive Sokolow-Lyon index at a cut-off
value of 27 mm. There were no substantial differences between the
sensitivity and specificity in the test cohort and validation cohort.
4 | DISCUSSION
In the current study, we demonstrated that in obesity patients,
established ECG criteria for the detection of LVH lack sufficient sensi-
tivity for application in daily clinical practice. We propose new criteria,
(RaVL+SV3)*BMI≥700 mm*kg/m2 for males and (SV1 + RV5/RV6)*
TABLE 1 Patient characteristics
Test
cohort
(n = 167)
Validation
cohort
(n = 100)
P-
value
Age (years) 61 ± 13 48 ± 8 <.001
Female, n (%) 123 (74%) 70 (70%) .49
Length (m) 1.67 ± 0.1 1.71 ± 0.1 .84
Weight (kg) 110 ± 15 127 ± 18 .27
BMI (kg/m2) 39 ± 4 43 ± 4 .20
BSA (m2) 2.3 ± 0.2 2.5 ± 0.2 <.001
Systolic BP (mmHg) 147 ± 25 142 ± 21 .09
Diastolic BP (mmHg) 76 ± 12 80 ± 12 .51
Heart rate (beats/min) 78 ± 16 71 ± 13 .048
Diabetes mellitus, n (%) 112 (67%) 21 (21%) <.001
Hypertension, n (%) 80 (48%) 31 (31%) .008
Left axis deviation, n (%) 16 (10%) 5 (5%) .22
RaVL + SV3 (mm)
(Cornell voltage)
11.8 ± 6 9.6 ± 5 .002
SV1 + RV5/RV6 (mm)
(Sokolow-Lyon index)
15.9 ± 6 15.7 ± 6 .81
SV4 + Sdeepest (mm)
(Peguero-Lo Presti criteria)
14.5 ± 5 12.1 ± 6 .001
LVM (g) 197 ± 67 196 ± 63 .83
LVM abnormal, n (%) 121 (72%) 69 (69%) .63
LVMI (g/m2) 94 ± 81 79 ± 22 .13
LVMI abnormal, n (%)a 53 (32%) 19 (19%) .026
Note: Values represent mean ± SD or n (%).
Abbreviations: BMI, body mass index; BP, blood pressure; BSA, body
surface area; LVM, left ventricular mass; LVMI, left ventricular mass index.
aUsed as the definition for LVH as defined by echocardiography.
TABLE 2 Criteria for LVH measured by ECG and echocardiography stratified by gender
Test cohort (n = 167) Validation cohort (n = 100)
Male (n = 44) Female (n = 123) P value Male (n = 30) Female (n = 70) P value
ECG criteria
Cornell voltage (mm) 14.8 ± 5.6 10.8 ± 5.6 <.001 11.1 ± 5.9 9.0 ± 0.4 .06
Cornell voltage abnormal, n (%) 3 (7%) 3 (2%) .18 1 (3%) 1 (1%) .37
Sokolow-Lyon index (mm) 15.4 ± 5.5 1.73 ± 7.6 .09 15.5 ± 5.5 15.8 ± 6.1 .82
Solow-Lyon abnormal, n (%) 1 (2%) 1 (1%) .45 0 1 (1%) .51
Peguero-Lo Presti criteria (mm) 17.7 ± 5.8 13.4 ± 4.6 <.001 12.7 ± 6.4 11.8 ± 5.3 .45
Peguero-Lo Presti abnormal n (%) 3 (7%) 4 (3%) .31 2 (7%) 4 (6%) .88
Echocardiography criteria
LVM (g) 258 ± 80 174 ± 43 <.001 242 ± 56 176 ± 55 <.001
LVM abnormal, n (%) 36 (82%) 85 (69%) .11 26 (87%) 43 (61%) .015
LVMI (g/m2) 124 ± 130 84 ± 49 .004 92 ± 21 75 ± 26 .002
LVMI abnormal, n (%) 19 (43%) 34 (28%) .06 5 (17%) 14 (20%) .67
Note: Values represent mean ± SD or n (%).
Abbreviations: LVM, left ventricular mass; LVMI, left ventricular mass index.
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TABLE 3 Accuracy of the Cornell voltage, Sokolow-Lyon index, Peguero-Lo Presti criteria and the BMI adjusted Cornell voltage for detection
of left ventricular hypertrophy in obesity patients using both the conventional cut-off points and the adjusted criteria
Test Cohort Gender Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Conventional cut-off points
Cornell voltage Male 16 (4-40) 100 (83-100) 100 (31-100) 61 (45-75)
Female 3 (0-17) 98 (91-100) 33 (2-87) 73 (63-80)
Sokolow-Lyon index Male 0 (0-21) 96 (78-100) 0 (0-95) 56 (40-71)
Female 3 (0-17) 100 (95-100) 100 (5-100) 73 (64-80)
Peguero-Lo Presti criteria Male 16 (4-40) 100 (83-100) 100 (31-100) 61 (45-75)
Female 9 (2-25) 99 (93-100) 75 (22-99) 74 (65-81)
Cornell voltage * BMIa Male 53 (29-75) 72 (50-87) 59 (33-81) 67 (46-83)
Female 32 (2-37) 85 (76-92) 46 (26-67) 80 (72-87)
Adjusted Criteria
Cornell voltage Male 16 (4–40) 100 (83-100) 100 (30-100) 61 (45-75)
Female 6 (1-21) 97 (90-99) 40 (7-83) 73 (64-80)
Sokolow-Lyon index Male 21 (7-46) 92 (72-99) 67 (24-94) 61 (43-76)
Female 18 (7-35) 97 (90-99) 67 (31-910 75 (66-82)
Peguero-Lo Presti criteria Male 32 (14-57) 96 (78-100) 86 (42-99) 65 (47-79)
Female 24 (11-42) 93 (85-97) 57 (30-81) 76 (67-84)
Cornell voltage * BMIa Male 47 (25-70) 96 (78-100) 90 (54-99) 71 (52-84)
Female 9 (2-25) 96 (88-99) 43 (12-80) 73 (64-81)
Sokolow Lyon index * BMIa Male 32 (14-57) 96 (78-100) 86 (42-99) 65 (47-79)
Female 26 (14-45) 93 (85-97) 60 (33-83) 77 (68-84)
Peguero Lo Presti criteria * BMIa Male 32 (14-57) 96 (78-100) 86 (42-99) 65 (47-79)
Female 24 (11-41) 96 (88-99) 67 (35-89) 77 (35-89)
Validation Cohort
Conventional cut-off points
Cornell voltage Male 20 (1-70) 100 (83-100) 100 (5-100) 86 (66-95)
Female 8 (0-38) 100 (92-100) 100 (5-100) 82 (70-90)
Sokolow-Lyon index Male 0 (0-54) 100 (83-100) -a 83 (64-93)
Female 0 (0-28) 98 (89-100) 0 (0-95) 80 (68-89)
Peguero-Lo Presti criteria Male 20 (1-70) 96 (77-100) 50 (3-97) 85 (65-95)
Female 15 (3-46) 96 (86-100) 50 (9-91) 82 (70-90)
Cornell voltage * BMIa Male 40 (7-83) 88 (67-98) 40 (7-83) 88 (67-97)
Female 23 (6-54) 87 (74-94) 30 (8-65) 82 (69-91)
Adjusted criteria
Cornell voltage Male 20 (1–70) 100 (83-100) 100 (5-100) 86 (66-95)
Female 8 (4-38) 98 (88-100) 50 (3-97) 81 (69-90)
Sokolow-Lyon index Male -a 100 (83-100) -a 83 (64-93)
Female 15 (2-46) 90 (78-96) 29 (5-70) 81 (68-90)
Peguero-Lo Presti criteria Male 20 (1–70) 96 (77-100) 50 (3-97) 85 (65-95)
Female 15 (3-46) 94 (83-99) 40 (7-83) 82 (70-90)
Cornell voltage * BMIa Male 40 (7-83) 92 (71-99) 50 (9-91) 88 (68-97)
Female 8 (0–38) 96 (86-99) 33 (2-87) 81 (69-89)
Sokolow Lyon index * BMIa Male 0 (0-54) 92 (72-99) 0 (0-80) 81 (61-93)
Female 23(6–54) 83 (70-91) 25 (7-57) 81 (68-90)
Peguero Lo Presti criteria * BMIa Male 20 (1-70) 96 (77–100) 50 (3-97) 85 (65-95)
Female 23 (6–54) 92 (81-98) 43 (12-79) 83 (71-91)
Abbreviations: BMI, body mass index; PPV, positive predictive value; NPV, negative predictive value.
aNone of the male patients in the validation cohort had a positive Sokolow-Lyon index.
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BMI≥885 mm*kg/m2 for females, for the detection of LVH in obesity
patients with improved sensitivity, without losing specificity.
The explanation of the poor sensitivity of the established ECG
criteria for detection of LVH (3%-9% in females and 0%-16% in males)
may be that obesity patients commonly have reduced voltages in the
precordial ECG leads, probably because the ECG voltages at the skin
level are attenuated by the subcutaneous adipose tissue.14 The sensi-
tivity of these criteria may be improved by adjustment of the cut-off
values and correction for BMI. Applying this, the Cornell voltage*BMI
for males and Sokolow-Lyon index*BMI for females, showed an
important improvement of the sensitivity of an ECG for the detection
of LVH in obesity patients to 47% and 26%, respectively, using the
optimal cut-off values (both identified in analysis using a fixed speci-
ficity of 95%).
Because in obesity patients with cardiac disease there may often
already be a clinical indication for an echocardiogram, an ECG as a
screening tool for detection of LVH may have the most value in obe-
sity patients without known cardiac disease. In the current study for
the first time, adjusted ECG criteria for the detection of LVH were
tested in such a relatively low-risk obese population. Even in these
subjects, the proposed new criteria performed fairly very well (sensi-
tivity of 40% for the Cornell voltage*BMI in males and 23% for the
Sokolow-Lyon index*BMI in females, using the optimal cut-off
values). Although these sensitivity values appear to be rather poor,
also in lean subjects the sensitivity of ECG criteria for LVH is known
to be limited. A review of multiple studies in different healthcare set-
tings found that the sensitivity of the Cornell voltage and Sokolow-
Lyon index ranged from 2% to 52% with a specificity ranging from
71% to 100%.24 Therefore, in our study, it was shown that the sensi-
tivity of an ECG to detect LVH in obesity patients without known car-
diac disease may be comparable to known sensitivity in lean subjects
when using the proposed new criteria.
When adjusting the Cornell voltage by BMI as designed by Angeli
et al.,17 the sensitivity of an ECG to detect LVH increased even to
53%; however, the specificity decreased to 72%. In previous
studies,10,14,22,23 a fixed specificity level of 95% was chosen because
this is supposed to be sufficient to render an ECG a cost-effective
alternative to echocardiography in screening populations for the pres-
ence of LVH. Therefore, we also used this 95% fixed specificity and
identified optimal sensitivity values by adjusting the cut-off values of
the criteria. Moreover, in the study by Angeli et al., this criterion was
not specifically tested in a group of obese patients. The mean BMI in
their cohort was 26.7 kg/m2, which is much lower than the mean BMI
of our test cohort and validation cohort (39 and 43 kg/m2,
respectively).
Some other studies regarding the optimization of ECG criteria for
the detection of LVH in obesity patients have been performed before.
Rider et al. made an adjustment to the cut-off value of the Sokolow-
Lyon index (+8 mm). This improved the sensitivity to 27% (specificity
93%) in their test cohort and 25% in their validation cohort.25 Also,
Robinson et al. designed a new criterion [RaVL + (BMI − 29) × 0.017],
which improved the sensitivity to 42%, however, with a relatively
decreased specificity of 83%.12 Finally, Rodrigues et al. made an
adjustment to the Cornell voltage (cut-off value ≥27 mm) which
improved the sensitivity to 21% with a specificity of 95%.23 Neverthe-
less, in none of these studies, the sensitivity of the established ECG
criteria for the detection of LVH in lean subjects was approached.
All adjusted criteria in our study had better sensitivities in
males than in females. This difference is possibly because of the
abundant breast tissue in obese women,26 which may also explain
why the Cornell voltage performed relatively poor in women
(Table 3). The positioning of lead V3, an important lead for the Cor-
nell voltage, is usually on a location of relatively plentiful breast tis-
sue as compared to the position of V1 and V5 used for the
Sokolow-Lyon index, which appeared to be the best performing cri-
terion in female obesity patients. An explanation could also be that
in general women have a smaller LVM (in our obese population
175 ± 48 g in females vs 252 ± 72 g in males, P < .001) leading to
smaller S wave amplitude in V3, which measures posteriorly
directed myocardial electrical activity.9,27
Finally, it may seem difficult to implement our proposed criteria
into daily practice since, apart from the necessity to assess BMI, it
would require the use of different criteria in males and females. How-
ever, nowadays ECG devices already use programmed algorithms for
standard interpretation. It will be a relatively minor issue to add our
proposed new criteria to these modern devices, allowing easy clinical
use without extra effort.
4.1 | Limitations
LVM was estimated by 2D echocardiography, despite reports demon-
strating superior accuracy of cardiac magnetic resonance imaging,
especially in obesity patients.28,29 However, echocardiography is
known to have good reproducibility for the diagnosis of LVH and
remains the most frequently used method in clinical practice.30 Also,
LVH diagnosed by ECG is known to be a marker of adverse electric
remodeling even without LVH diagnosed by echocardiography. Thus,
also without association with echocardiographic LVH, some ECG
criteria may still be associated with prognosis.31,32 Although obesity is
usually defined as BMI ≥30 kg/m2, all patients included in our study
had a BMI ≥35 kg/m2 because this was an inclusion criterion for the
CARDIOBESE study. Therefore, the conclusions may only be applied
to morbidly obese patients and not to obesity patients in general. The
sample size was relatively small. The validation cohort had a relatively
low prevalence of LVH; therefore, the PPV values even for the new
criteria were low. However, as mentioned before, in the current study
for the first time, adjusted ECG criteria for the detection of LVH were
validated in a relatively low-risk obese population without known or
suspicion of cardiovascular disease. Racial differences in the diagnosis
of LVH were not addressed in this study. Also, the abilities of the pro-
posed criteria to predict outcomes (eg, incident cardiovascular mor-
bidity) are not known. Finally, we included only BMI as an obesity
index and could not assess whether, for example, waist circumference
or epicardial fat thickness is superior to BMI to adjust the voltage
ECG criteria.
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5 | CONCLUSIONS
Established ECG criteria for the detection of LVH lack sufficient sensi-
tivity in obesity patients. We propose new criteria, (RaVL+SV3)*BMI
≥700 mm*kg/m2 for males and (SV1 + RV5/RV6)*BMI ≥885 mm*kg/
m2 for females, for the detection of LVH in obesity patients with
improved sensitivity (47% in males and 26% in females), approaching
known sensitivity of the most commonly used ECG criteria in lean
subjects.
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